ReviewMolecular biology reports2026
Carbohydrates metabolic reprogramming and tumor microenvironment in pancreatic cancer: targeting pathways.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is highly malignant, with a five-year overall survival rate of less than 10%. Its diagnosis is often challenging and delayed, and treatment options remain limited. Carbohydrate metabolic reprogramming plays a critical role in pancreatic cancer development, accompanied by the dysregulation of various genes, enzymes, and signaling pathways involved in glycolysis and the pentose phosphate pathway (PPP). These alterations support tumor survival and rapid growth. Targeting these disrupted metabolic pathways with emerging compounds may help overcome chemoresistance and increase senstivity of tumor cells to drugs, making it a promising therapeutic strategy. This review first outlines, the genes and enzymes that are upregulated in glycolysis and PPP in pancreatic ductal adenocarcinoma (PDAC). It then discusses small-molecule drugs and monoclonal antibodies that target these key pathways to control tumor progression. Finally, it examins the connection between carbohydrate metabolic reprogramming and the tumor microenvironment (TME), highlighting its potential role in the development of targeted therapies to improve patient outcomes.
Indexed as
Identifiers
42536269What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.